Tinzaparin in the treatment of venous thromboembolism

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 12, 2003, Pages 2355-2362

  Pineo, Graham F ^a   Hull, Russell D ^a  

^a FOOTHILLS HOSPITAL   (Canada)

Author keywords

Deep vein thrombosis; Heparin; Low molecular weight heparin; Pulmonary embolism; Tinzaparin; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; CREATININE; DALTEPARIN; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN; WARFARIN;

ARTICLE; BLEEDING; BODY MASS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG USE; ECONOMICS; ELDERLY CARE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; LUNG EMBOLISM; META ANALYSIS; MORTALITY; OBESITY; ORAL DRUG ADMINISTRATION; PATIENT CARE; PREGNANCY; RECURRENT DISEASE; THROMBOEMBOLISM; VEIN THROMBOSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFUSIONS, INTRAVENOUS; PREGNANCY; PULMONARY EMBOLISM; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0345735595     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.12.2355     Document Type: Article

References (38)

1. ANDERSON FA, WHEELER HB, GOLDBERG RJ et al.: A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis within a defined urban population. The Worcester DVT Study. J. Intern. Med. (1992) 232:155-160.
2. HIRSH J, WARKENTIN TE, SHAUGHNESSY SG et al.: Reparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest (2001) 119(Suppl. 1):64S-94S.
3. HYERS TM, AGNELLI G, HULL RD et al.: Antithrombotic therapy for venous thromboembolic disease. Chest (2001) 119(Suppl. 1):176S-93S.
4. WEITZ JI: Low molecular weight heparins. N. Engl. J. Med. (1997) 337:688-698.
5. FRIEDEL HA, BALFOUR JA: Tinzaparin: A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs (1994) 48(4):638-660.
6. CROWTHER MA, BERRY LR, MONAGLE PT, CHAN AKC: Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br. J. Haemat. (2002) 116:178-186.
7. BARA L, PLANES A, SAMAMA MM: Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin of tinzaparin, to prevent deep vein thrombosis after hip surgery. Br. J. Haemat. (1999) 104:230-240.
8. MOUSA SA: The low molecular weight heparin, Tinzaparin, in thrombosis and beyond. Cardiovasc. Drug Rev. (2002) 20(Suppl. 3):163-180.
9. BARRETT JS, KORNHAUSER DH, HAINER JW et al.: Anticoagulant pharmacodynamics of tinzaparin following 175 IU/kg subcutaneous administration to healthy volunteers. Thromb. Res. (2001) 101:243-254.
10. BARRETT JS, GIBIANSKY E, HULL RD et al.: Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. Intern. J. Clin. Pharmacol. Ther. (2001) 39(10):431-446.
11. SIGURET V, PAUTAS E, FEVRIER M et al.: Elderly patients treated with tinzaparin (Innohep®) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb. Haemost. (2000) 84(5):800-804.
12. PAUTAS E, GOUIN I, BELLOT O, ANDREUX J-P, SIGURET V: Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf. (2002) 25(10):725-733.
13. NAGGE J, CROWTHER M, HIRSH J: Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch. Intern. Med. (2002) 162:2605-2609.
14. MISMETTI P, LAPORTA-SIMITSIDIS S, NAVARRO C et al.: Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb. Haemost. (1998) 79:1162-1165.
15. SANDERINK GJ, GUIMART C, JARIWALA N et al.: Enoxaparin pharmacokinetics and pharmacodynamics in renal impairment. J. Am. Coll. Cardiol. (2001) 37(Suppl. A):229A (Abstract).
16. SIEGBAHN A, Y-HASSAN S, BOBERG J et al.: Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin: a dose finding study with LMWH-Novo. Thromb. Res. (1989) 55:767-778.
17. HULL RD, RASKOB GE, PINEO GF et al.: Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N. Engl. J. Med. (1992) 326:975-982.
18. HULL RD, RASKOB GE, ROSENBLOOM D et al.: Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch. Intern. Med. (1992) 152:1589-1595.
19. HULL RD, DELMORE T, GENTON E et al.: Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N. Engl. J. Med. (1979) 301:855-858.
20. HULL RD, HIRSH J, JAY R et al.: Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N. Engl. J. Med. (1982) 307:1676-1681.
21. HULL RD, RASKOB GE, HIRSH J et al.: Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N. Engl. J. Med. (1986) 315:1109-1114.
22. HULL RD, RASKOB GE, ROSENBLOOM D et al.: Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N. Engl. J. Med. (1990) 322:1260-1264.
23. HULL RD, RASKOB GE, ROSENBLOOM D et al.: Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin versus intravenous heparin: an economic perspective. Arch. Intern. Med. (1997) 157:289-294.
24. CARO JJ, GETSIOS D, CARO I, O'BRIEN JA: Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis. Pharmacoeconomics (2002) 20(9):593-602.
25. SIMONNEAU G, SORS H, CRARBONNIER B et al.: A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N. Engl. J. Med. (1997) 337:663-669.
26. HULL RD, PINEO GF, SIMONNEAU G et al.: A meta-analysis of a once daily regimen using tinzaparin for the treatment of patients with proximal deep-vein thrombosis and complicating objectively documented pulmonary embolism. Chest (2000) 118(4):Suppl. 81S.
27. GOULD MK, DEMBITZER AD, DOYLE RL, HASTIE TJ, GARBER AM: Low-molecular-weight hepatitis compared with unfractionated heparin for treatment of acute deep vein thrombosis - a meta-analysis of randomized, controlled trials. Ann. Intern. Med. (1999) 130:800-809.
28. VAN DER HEIJDEN JF, HUTTEN BA, BULLER HR, PRINS MH: Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism (Cochrane Review). The Cochrane Library (2001) 2:1-2.
29. LEE AYY, LEVINE MN, BAKER RI et al.: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. (2003) 349(Suppl. 2):146-153.
30. HULL RD, PINEO GF, MAH AF, BRANT RF, FOR THE LITE STUDY INVESTIGATORS: A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Blood (2002) 100(11):148a.
31. HULL RD, PINEO GF, MAH AF, BRANT RF, FOR THE LITE STUDY INVESTIGATORS. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium in patients with current cancer. J. Thromb. Haemost. (2003) 1(Suppl. 1):P1373a.
32. HULL RD, PINEO GF, MAH AF, BRANT RF, FOR THE LITE STUDY INVESTIGATORS: HOME-LITE: safety and efficacy results for a study investigating the long-term out-of-hospital treatment of patients with proximal venous thrombosis using subcutaneous low-molecular-weight heparin versus warfarin. J. Thromb. Haemost. (2003) 1(Suppl. 1):OC1647.
33. HULL RD, PINEO GF, MAH AF, BRANT RF, FOR THE LITE STUDY INVESTIGATORS: HOME-LITE: quality of life results for a study investigating the long-term out-of-hospital treatment of patients with proximal-vein thrombosis using subcutaneous low-molecular-weight heparin versus warfarin. J. Thromb. Haemost. (2003) 1(Suppl. 1):P2328.
34. HULL RD, RASKOB GE, PINEO GF et al.: A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N. Engl. J. Med. (2003) 329:1370-1376.
35. PLANES A, SAMAMA MM, LENSING AWA et al.: 1999 Prevention of deep vein thrombosis after hip replacement: comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin. Thromb. Haemost. (1999) 81:22-25.
36. HAINER JW, BARRETT JS, ASSAID CA et al.: Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb. Haemost. (2002) 87:817-823.
37. SMITH MP, NORRIS LA, STANLEY JL et al.: Innohep in pregnancy: a dose finding study of subcutaneous tinzaparin for thrombosis treatment and prevention during pregnancy. Blood (2000) 96(11):949a.
38. GINSBERG JS, GREER I, HIRSH J: Use of antithrombotic agents during pregnancy. Chest (2001) 119:122S-131S.